EcoDrugPlus

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSCPOG00000015651
Gene Symbol: SCN8A
2 Cross references
276 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 9

Ensembl ID : ENSCPOG00000013017
Gene Symbol: SCN9A
2 Cross references
109 Possible Orthologues:

Solute Carrier Family 10 Member 2

Ensembl ID : ENSCPOG00000001207
Gene Symbol: SLC10A2
2 Cross references
211 Possible Orthologues:

Solute Carrier Family 18 Member A2

Ensembl ID : ENSCPOG00000003595
Gene Symbol: SLC18A2
4 Cross references
222 Possible Orthologues:

Solute Carrier Family 22 Member 12

Ensembl ID : ENSCPOG00000020117
Gene Symbol: SLC22A12
4 Cross references
475 Possible Orthologues:

Solute Carrier Family 22 Member 6

Ensembl ID : ENSCPOG00000015195
Gene Symbol: SLC22A6
2 Cross references
495 Possible Orthologues:

Solute Carrier Family 22 Member 8

Ensembl ID : ENSCPOG00000007880
Gene Symbol: SLC22A8
2 Cross references
304 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSCPOG00000005137
Gene Symbol: SLC29A1
2 Cross references
280 Possible Orthologues:

Solute Carrier Family 5 Member 1

Ensembl ID : ENSCPOG00000007281
Gene Symbol: SLC5A1
4 Cross references
250 Possible Orthologues:

Solute Carrier Family 5 Member 2

Ensembl ID : ENSCPOG00000011533
Gene Symbol: SLC5A2
2 Cross references
198 Possible Orthologues:

Solute Carrier Family 6 Member 1

Ensembl ID : ENSCPOG00000025521
Gene Symbol: SLC6A1
2 Cross references
279 Possible Orthologues:

Solute Carrier Family 6 Member 2

Ensembl ID : ENSCPOG00000002271
Gene Symbol: SLC6A2
4 Cross references
204 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).